Background The metastatic rate and risk factors of splenic hilar (No.10) lymph nodes (LNs) in gastric adenocarcinoma were still variable and uncertain, and the prognostic significance of No.10 LNs was also controversial. The aim of this retrospective study was to analyze the metastatic rate, risk factors and prognostic significance of No.10 LNs in gastric adenocarcinoma. Methods From August 2007 to December 2011, 205 patients who were diagnosed with primary gastric adenocarcinoma and underwent total or proximal gastrectomy plus No.10 LNs dissection in West China Hospital were enrolled. Clinicopathological features and survival outcomes were retrospectively analyzed. Results Mean numbers of harvested LNs and metastatic LNs were 34.8±12.6 (15–73) and 8.7±10.8 (0–67), respectively. The proportion of cases with positive No.10 LNs was 8.8% (18/205). In all 204 dissected No.10 LNs, 47 LNs (23.0%) were metastatic. In 52.2% (107/205) patients, the dissected splenic hilar tissues were histologically determined as only fat tissues but without LNs structure. Histological evidence of LNs structure was found in 98 (47.8%) patients with 18.4% (18/98) metastatic No.10 LNs. In multivariate logistic regression analysis, metastasis of No.10 LNs was significantly correlated with No.4sa LNs (p = 0.010) and pN stage (p = 0.012). Regarding survival analysis, 199 (97.1%) patients were followed up (0.6–74.8 months). In all patients with R0 resection, metastatic No.10 LNs caused significantly worse prognosis both in Kaplan-Meier (p = 0.006) and Cox regression analysis (p = 0.031). Conclusions Although the metastatic rate of No.10 LNs was 8.8%, dissection of No.10 LNs might be meaningful due to the poor prognosis of positive cases. And attentions should be also paid to its correlated factors including pN stage and No.4sa LNs.
References
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, et al. (2008) Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol 14: 2715–2722. doi: 10.3748/wjg.14.2715
[3]
Ajani JA (1998) Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12: 44–47.
[4]
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: 439–449. doi: 10.1016/s1470-2045(10)70070-x
[5]
Hu JK, Yang K, Zhang B, Chen XZ, Chen ZX, et al. (2009) D2 Plus Para-Aortic Lymphadenectomy Versus Standardized D2Lymphadenectomy in Gastric Cancer Surgery. Surg Today 39: 207–213. doi: 10.1007/s00595-008-3856-x
[6]
Chen XZ, Hu JK, Zhou ZG, Rui YY, Yang K, et al. (2010) Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. J Am Coll Surg 210: 100–105. doi: 10.1016/j.jamcollsurg.2009.09.033
[7]
Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, et al. (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125: 666–673. doi: 10.1002/ijc.24290
Japanese gastric cancer association (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14: 113–123. doi: 10.1007/s10120-011-0042-4
[10]
Okajima K, Isozaki H (1995) Splenectomy for treatment of gastric cancer: Japanese experience. World J Surg 19: 537–540. doi: 10.1007/bf00294715
[11]
Ishikawa S, Shimada S, Miyanari N, Hirota M, Takamori H, et al. (2009) Pattern of lymph node involvement in proximal gastric cancer. World J Surg 33: 1687–1692. doi: 10.1007/s00268-009-0083-6
[12]
M？nig SP, Collet PH, Baldus SE, Schmackpfeffer K, Schr？der W, et al. (2001) Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus. J Surg Oncol 76: 89–92. doi: 10.1002/1096-9098(200102)76:2<89::aid-jso1016>3.3.co;2-9
[13]
Sasako M, McCulloch P, Kinoshita T, Maruyama K (1995) New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 82: 346–351. doi: 10.1002/bjs.1800820321
[14]
Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, et al. (2007) Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg 11: 1039–1044. doi: 10.1007/s11605-007-0186-z
[15]
Yu W, Choi GS, Chung HY (2006) Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 93: 559–563. doi: 10.1002/bjs.5353
[16]
Maehara Y, Moriguchi S, Yoshida M, Takahashi I, Korenaga D, et al. (1991) Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 67: 3006–3009. doi: 10.1002/1097-0142(19910615)67:12<3006::aid-cncr2820671213>3.0.co;2-v
[17]
Shin SH, Jung H, Choi SH, An JY, Choi MG, et al. (2009) Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol 16: 1304–1309. doi: 10.1245/s10434-009-0389-5
[18]
Fatouros M, Roukos DH, Lorenz M, Arampatzis I, Hottentrott C, et al. (2005) Impact of spleen preservation in patients with gastric cancer. Anticancer Res 25: 3023–3030.
[19]
Nashimoto A, Yabusaki H, Matsuki A (2012) The significance of splenectomy for advanced proximal gastric cancer. Int J Surg Oncol 2012: 301530S doi:10.1155/2012/301530.
[20]
Zhu GL, Sun Z, Wang ZN (2012) Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach. J Surg Oncol 105: 786–792. doi: 10.1002/jso.22149
[21]
Keishiro A, Kikuo K, Motoshi M, Imaizumi T, Kizaki J, et al. (2010) Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepato 2: 81–86.
[22]
Chikara K, Hiroshi S, Masato N, Hirotoshi A, Goro M, et al. (2001) Indications for pancreaticosplenectomy in advanced gastric cancer. Hepatogastroenterology 48: 908–912.
[23]
Ikeguchi M, Kaibara N (2004) Lymph node metastasis at the splenic hilum in proximal gastric cancer. Am Surg 70: 645–648.
[24]
Degiuli M, Sasako M, Ponzetto A, Allone T, Soldati T, et al. (1997) Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol 23: 310–314. doi: 10.1016/s0748-7983(97)90696-x
[25]
Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, et al. (2002) A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 131: 401–407. doi: 10.1067/msy.2002.121891
[26]
Okinaga K, Iinuma H, Kitamura Y, Yokohata T, Inaba T, et al. (2006) Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer. J Exp Clin Cancer Res 25: 339–349.
[27]
Yang K, Chen XZ, Hu JK, Zhang B, Chen ZX, et al. (2009) Effectiveness and safety of splenectomy for gastric carcinoma: A meta-analysis. World J Gastroenterol 15: 5352–5359. doi: 10.3748/wjg.15.5352
[28]
Japanese gastric cancer association (2011) Japanese classification of gastric carcinoma: 3rd English version. Gastric Cancer 14: 101–112. doi: 10.1007/s10120-011-0041-5
[29]
Zhang CH, Wu AW, Li ZY, Zhang LH, Bu ZD, et al. (2011) Analysis of splenic hilar lymph node metastasis in advanced gastric cancer and dissection techniques. Zhong Hua Wei Chang Wai Ke Za Zhi 14: 589–592. Chinese
[30]
Wen L, Chen XZ, Wu B, Chen XL, Wang L, et al. (2012) Total vs. Proximal gastrectomy for proximal gastric cancer: a systematic review and meta-analysis. Hepatogastroenterology 59: 633–640. doi: 10.5754/hge11834
